Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 2,212 Shares

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now owns 19,386 shares in the company, valued at $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Natera Trading Down 3.3 %

Shares of NASDAQ:NTRA opened at $146.06 on Monday. The company has a market cap of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera, Inc. has a 1 year low of $52.01 and a 1 year high of $167.79. The stock’s fifty day moving average price is $127.38 and its 200-day moving average price is $115.76.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. Sell-side analysts expect that Natera, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group lifted their price target on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. JPMorgan Chase & Co. lifted their price target on Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. TD Cowen lifted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Canaccord Genuity Group lifted their price target on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $137.65.

Institutional Trading of Natera

A number of hedge funds have recently bought and sold shares of NTRA. Wellington Management Group LLP increased its position in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Farallon Capital Management LLC increased its position in Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares during the last quarter. First Light Asset Management LLC increased its position in Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after acquiring an additional 490,822 shares during the last quarter. AQR Capital Management LLC increased its position in Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after acquiring an additional 469,327 shares during the last quarter. Finally, PointState Capital LP increased its position in Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after buying an additional 413,468 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.